Sly syndrome: Difference between revisions
No edit summary |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Sly syndrome | |||
| image = [[File:autorecessive.svg|200px]] | |||
| caption = Sly syndrome is inherited in an [[autosomal recessive]] pattern. | |||
| synonyms = [[Mucopolysaccharidosis type VII]], MPS VII | |||
| pronounce = | |||
| specialty = [[Medical genetics]] | |||
| symptoms = [[Hepatosplenomegaly]], [[skeletal dysplasia]], [[developmental delay]] | |||
| onset = [[Infancy]] | |||
| duration = [[Lifelong]] | |||
| causes = Mutations in the [[GUSB]] gene | |||
| risks = | |||
| diagnosis = [[Genetic testing]], [[urine test]] for [[glycosaminoglycans]] | |||
| differential = Other [[mucopolysaccharidoses]] | |||
| prevention = | |||
| treatment = [[Enzyme replacement therapy]], [[hematopoietic stem cell transplantation]] | |||
| medication = | |||
| prognosis = Variable, depending on severity | |||
| frequency = Rare | |||
| deaths = | |||
}} | |||
{{Short description|An overview of Sly syndrome, a rare genetic disorder}} | {{Short description|An overview of Sly syndrome, a rare genetic disorder}} | ||
'''Sly syndrome''', also known as '''mucopolysaccharidosis type VII''' (MPS VII), is a rare [[autosomal recessive]] [[lysosomal storage disorder]] caused by a deficiency of the enzyme [[beta-glucuronidase]]. This enzyme deficiency leads to the accumulation of [[glycosaminoglycans]] (GAGs) in various tissues and organs, resulting in a wide range of clinical manifestations. | '''Sly syndrome''', also known as '''mucopolysaccharidosis type VII''' (MPS VII), is a rare [[autosomal recessive]] [[lysosomal storage disorder]] caused by a deficiency of the enzyme [[beta-glucuronidase]]. This enzyme deficiency leads to the accumulation of [[glycosaminoglycans]] (GAGs) in various tissues and organs, resulting in a wide range of clinical manifestations. | ||
==Genetics== | ==Genetics== | ||
Sly syndrome is inherited in an [[autosomal recessive]] manner, meaning that an individual must inherit two copies of the defective gene, one from each parent, to manifest the disease. The gene responsible for Sly syndrome is located on [[chromosome 7]] and is known as the [[GUSB]] gene. Mutations in this gene lead to reduced or absent activity of the beta-glucuronidase enzyme. | Sly syndrome is inherited in an [[autosomal recessive]] manner, meaning that an individual must inherit two copies of the defective gene, one from each parent, to manifest the disease. The gene responsible for Sly syndrome is located on [[chromosome 7]] and is known as the [[GUSB]] gene. Mutations in this gene lead to reduced or absent activity of the beta-glucuronidase enzyme. | ||
==Pathophysiology== | ==Pathophysiology== | ||
The deficiency of beta-glucuronidase in Sly syndrome results in the accumulation of [[glycosaminoglycans]] such as [[dermatan sulfate]], [[heparan sulfate]], and [[chondroitin sulfate]] in the [[lysosomes]] of cells. This accumulation disrupts normal cellular function and leads to the progressive damage of tissues and organs. | The deficiency of beta-glucuronidase in Sly syndrome results in the accumulation of [[glycosaminoglycans]] such as [[dermatan sulfate]], [[heparan sulfate]], and [[chondroitin sulfate]] in the [[lysosomes]] of cells. This accumulation disrupts normal cellular function and leads to the progressive damage of tissues and organs. | ||
==Clinical Features== | ==Clinical Features== | ||
The clinical presentation of Sly syndrome can vary widely among affected individuals. Common features include: | The clinical presentation of Sly syndrome can vary widely among affected individuals. Common features include: | ||
| Line 16: | Line 35: | ||
* [[Cardiac abnormalities]] | * [[Cardiac abnormalities]] | ||
* [[Corneal clouding]] | * [[Corneal clouding]] | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of Sly syndrome is typically made through a combination of clinical evaluation, biochemical testing, and genetic analysis. Measurement of beta-glucuronidase activity in leukocytes or fibroblasts can confirm the diagnosis. Genetic testing can identify mutations in the [[GUSB]] gene. | Diagnosis of Sly syndrome is typically made through a combination of clinical evaluation, biochemical testing, and genetic analysis. Measurement of beta-glucuronidase activity in leukocytes or fibroblasts can confirm the diagnosis. Genetic testing can identify mutations in the [[GUSB]] gene. | ||
==Management== | ==Management== | ||
Currently, there is no cure for Sly syndrome, and treatment is primarily supportive and symptomatic. Management may include: | Currently, there is no cure for Sly syndrome, and treatment is primarily supportive and symptomatic. Management may include: | ||
| Line 25: | Line 42: | ||
* [[Hematopoietic stem cell transplantation]] | * [[Hematopoietic stem cell transplantation]] | ||
* Symptomatic treatment for cardiac and respiratory complications | * Symptomatic treatment for cardiac and respiratory complications | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for individuals with Sly syndrome varies depending on the severity of the disease. Early diagnosis and intervention can improve quality of life and outcomes for affected individuals. | The prognosis for individuals with Sly syndrome varies depending on the severity of the disease. Early diagnosis and intervention can improve quality of life and outcomes for affected individuals. | ||
==See also== | |||
== | |||
* [[Mucopolysaccharidosis]] | * [[Mucopolysaccharidosis]] | ||
* [[Lysosomal storage disorder]] | * [[Lysosomal storage disorder]] | ||
* [[Autosomal recessive disorder]] | * [[Autosomal recessive disorder]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Lysosomal storage diseases]] | [[Category:Lysosomal storage diseases]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] {{stub}} | ||
Latest revision as of 22:59, 6 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Sly syndrome | |
|---|---|
| File:Autorecessive.svg | |
| Synonyms | Mucopolysaccharidosis type VII, MPS VII |
| Pronounce | |
| Specialty | Medical genetics |
| Symptoms | Hepatosplenomegaly, skeletal dysplasia, developmental delay |
| Complications | N/A |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Mutations in the GUSB gene |
| Risks | |
| Diagnosis | Genetic testing, urine test for glycosaminoglycans |
| Differential diagnosis | Other mucopolysaccharidoses |
| Prevention | |
| Treatment | Enzyme replacement therapy, hematopoietic stem cell transplantation |
| Medication | |
| Prognosis | Variable, depending on severity |
| Frequency | Rare |
| Deaths | |
An overview of Sly syndrome, a rare genetic disorder
Sly syndrome, also known as mucopolysaccharidosis type VII (MPS VII), is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme beta-glucuronidase. This enzyme deficiency leads to the accumulation of glycosaminoglycans (GAGs) in various tissues and organs, resulting in a wide range of clinical manifestations.
Genetics[edit]
Sly syndrome is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the defective gene, one from each parent, to manifest the disease. The gene responsible for Sly syndrome is located on chromosome 7 and is known as the GUSB gene. Mutations in this gene lead to reduced or absent activity of the beta-glucuronidase enzyme.
Pathophysiology[edit]
The deficiency of beta-glucuronidase in Sly syndrome results in the accumulation of glycosaminoglycans such as dermatan sulfate, heparan sulfate, and chondroitin sulfate in the lysosomes of cells. This accumulation disrupts normal cellular function and leads to the progressive damage of tissues and organs.
Clinical Features[edit]
The clinical presentation of Sly syndrome can vary widely among affected individuals. Common features include:
- Hepatosplenomegaly
- Skeletal dysplasia
- Developmental delay
- Hydrops fetalis in severe cases
- Cardiac abnormalities
- Corneal clouding
Diagnosis[edit]
Diagnosis of Sly syndrome is typically made through a combination of clinical evaluation, biochemical testing, and genetic analysis. Measurement of beta-glucuronidase activity in leukocytes or fibroblasts can confirm the diagnosis. Genetic testing can identify mutations in the GUSB gene.
Management[edit]
Currently, there is no cure for Sly syndrome, and treatment is primarily supportive and symptomatic. Management may include:
- Enzyme replacement therapy
- Hematopoietic stem cell transplantation
- Symptomatic treatment for cardiac and respiratory complications
Prognosis[edit]
The prognosis for individuals with Sly syndrome varies depending on the severity of the disease. Early diagnosis and intervention can improve quality of life and outcomes for affected individuals.
See also[edit]
 | |
|---|---|
 |
 |
